vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, is pleased to announce that enrolment into the pivotal European NOSTRA III (NO Synthase in TRAumatic Brain Injury) clinical trial is completed. vasopharm remains on track to deliver headline data by end of 2020.
NOSTRA III is a 220 patient Phase III clinical trial assessing efficacy and safety of Ronopternin (VAS203) for the treatment of moderately to severely injured closed head traumatic brain (TBI) injury patients. The study is being conducted in 35 leading European trauma centres. In accordance with the study protocol which requires an evaluation of the extended Glasgow Outcome Scale (eGOS) six months post-trauma, the company anticipates last patient – last visit in June 2020 and full clinical data analysis by end of 2020. The full study protocol has been published in the peer-reviewed journal ‘Trials’ *.